FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Washington, D.	C. 20549
----------------	----------

STATEMENT OF CHANGES IN BENEFICIAL OWNE	ERSHIP

OMB APPROVAL		
OMB Number:	3235-0287	
Estimated average burden		
hours per response:	0.5	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer 1. Name and Address of Reporting Person\* (Check all applicable) Dyne Therapeutics, Inc. [ DYN ] Beskrovnaya Oxana Director 10% Owner Officer (give title Other (specify below) below) 3. Date of Earliest Transaction (Month/Day/Year) (Middle) Chief Scientific Officer 06/02/2021 C/O DYNE THERAPEUTICS, INC. 830 WINTER STREET 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) (Street) Form filed by One Reporting Person **WALTHAM** 02451 MA Form filed by More than One Reporting (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 5. Amount of 7. Nature of Indirect Beneficial Execution Date Transaction Securities Beneficially
Owned Following (Month/Day/Year) if any (Month/Day/Year) Code (Instr. Ownership Reported (Instr. 4) Transaction(s) (Instr. 3 and 4) ٧ Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 3. Transaction Date 1. Title of 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount 8. Price of 9. Number of 11. Nature Transaction Code (Instr. 8) Conversion Derivative Ownership Derivative Execution Date. Derivative **Expiration Date** of Securities derivative of Indirect or Exercise Price of Derivative (Month/Day/Year) if any (Month/Day/Year) Underlying Derivative Security (Instr. 3 and 4) Security (Instr. 3) Securities (Month/Day/Year) Security (Instr. 5) Securities Beneficially Form: Direct (D) Beneficial Acquired (A) Ownership (Instr. 4) Owned Following or Disposed of (D) (Instr. 3, 4 and 5) Security (I) (Instr. 4) Reported Transaction(s) (Instr. 4) Amount Number of Shares Date Exercisable (A) (D) Title Code Stock

\$19.05

1. This option was granted on June 2, 2021. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on June 2, 2022 and the remaining shares vesting in equal quarterly installments thereafter.

110 000

(1)

## Remarks:

Option

(right to buy)

> /s/ Richard Scalzo, Attorney-in-06/02/2021

110,000

\$0.00

110 000

D

**Fact** 

06/01/2031

Commor

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/02/2021

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Α

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.